Inozyme Pharma, Inc. Common Stock

Inozyme Pharma announced the postponement of its 2025 Annual Meeting of Stockholders due to the previously announced acquisition by BioMarin Pharmaceutical Inc. The company is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics targeting the PPi-Adenosine Pathway.

Related tickers: INZY, BMRN.

Halper Sadeh LLC is investigating several companies, including SpringWorks Therapeutics, NV5 Global, Charter Communications, and Inozyme Pharma, for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

Related tickers: SWTX, NVEE, CHTR, INZY.